Resveratrol is one of the most frequently combined compounds in NAD+-related supplements. Products containing „NAD+ with resveratrol” are widely promoted, mainly because both compounds are linked to sirtuin biology, metabolism and ageing research. The scientific rationale for this combination is interesting, but at the same time more uncertain than marketing often suggests. In this article, we explain what resveratrol is, why it is combined with NAD+ precursors, what the sirtuin-related theory is based on, what human studies actually confirm, and how combined products compare to separate formulations.
What is resveratrol and why is it linked to NAD+?
Resveratrol is a naturally occurring polyphenol present in the skins of red grapes, red wine, certain berries and several other plants.
He became widely known at the beginning of the 21st century for research related to the so-called „French paradox”, which is the observation that some populations consuming relatively large amounts of wine appeared to have a relatively low level of cardiovascular disease.
Since then, resveratrol has become one of the most intensively studied polyphenols in the context of ageing, metabolism, inflammation and cellular stress responses.
Its connection with NAD+ stems mainly from early research into sirtuins.
A highly influential 2003 study identified resveratrol as an activator of SIRT1, one of the seven human enzymes belonging to the sirtuin family [1].
Sirtuins require NAD+ as a substrate to function properly. This has created a straightforward biological rationale for combining both compounds.
In this model, NAD+ precursors are intended to increase NAD+ availability, while resveratrol is supposed to influence SIRT1 activity. The combination has therefore become a popular way of targeting the same biological pathway from two different angles.
Justification related to the activation of sirtuins
The initial 2003 study showed that resveratrol reduced the amount of NAD+ needed for SIRT1 to function effectively [1].
The same study also found that resveratrol extended the replicative lifespan of yeast by approximately 70% via a mechanism linked to SIRT1, producing effects reminiscent of certain characteristics of calorie restriction [1].
These results had a major impact on subsequent research. They contributed to significant scientific and commercial interest in resveratrol, sirtuins, and later also strategies related to NAD+ and ageing.
However, the proposed mechanism of direct SIRT1 activation has become a subject of controversy.
Later biochemical studies used natural substrates instead of the fluorescently labelled substrates that had been used in some of the earlier experiments. Under such conditions, resveratrol did not directly activate SIRT1 in the same way [2].
Researchers suggested that some of the earlier observed activation could have depended on the fluorescent labelling technique used, rather than the general effect of resveratrol on natural SIRT1 substrates [2].
The same study also showed that resveratrol did not improve mitochondrial capacity or lower blood glucose levels in a mouse model in the way that would be expected from a strong direct SIRT1-activating effect [2].
This means that the most commonly cited explanation for combining resveratrol with NAD+ precursors is not scientifically proven.
The theory remains historically important and biologically plausible, but the direct activation of SIRT1 by resveratrol has been challenged by subsequent experimental studies.
Resveratrol may still influence metabolism, cellular stress response, inflammation and ageing-related pathways through other mechanisms.
However, the straightforward statement that resveratrol directly activates SIRT1 while NAD+ provides it with the necessary „fuel” presents this biology with greater certainty than current evidence allows.
Do studies support combining NAD+ and resveratrol?
Direct human data regarding this specific combination remains limited.
No published, controlled human clinical trial directly testing an NAD+ precursor together with resveratrol itself has been identified.
The closest available data from human studies come from research on nicotinamide riboside combined with pterostilbene.
Pterostilbene is chemically related to resveratrol and has been studied for some similar biological properties, but it is a distinct compound with different pharmacokinetic properties, including better oral bioavailability.
In one clinical trial with multiple dosing, the combination of NR and pterostilbene was evaluated and shown to safely and sustainingly increase NAD+ levels over the study period [3].
This constitutes controlled evidence from human studies that such a combination can increase NAD+ biomarkers.
However, the study did not concern resveratrol itself.
Nor did it include control groups receiving NR and pterostilbene separately in a manner that would clearly determine whether pterostilbene provided an additional benefit over the effect of NR alone.
The current evidence therefore consists of two distinct elements.
Firstly, there is an influential, yet scientifically questioned, mechanistic justification for combining resveratrol with NAD+ precursors [1,2].
Secondly, there is human clinical trial data on NR combined with a related compound, pterostilbene [3].
However, there is a lack of direct, controlled human trial data showing that the combination of an NAD+ precursor and resveratrol provides a specific synergistic benefit.
Claims that precisely this combination has been clinically proven to be more effective than either of these compounds used alone are therefore not supported by dedicated combination studies.
Typical dosages and administration times in combination products
A clinically optimal ratio of the NAD+ precursor to resveratrol has not been established.
The main reason is that the exact combination has not been studied in dedicated, controlled human trials.
The closest data concerning combination therapy come from studies using NR together with pterostilbene [3], whereas resveratrol itself has been evaluated separately in a wide range of human studies.
In resveratrol research, doses ranging from approximately 150 mg to 1,000 mg per day or more have generally been used, depending on the studied population and the evaluated outcome.
These ranges come from general research on resveratrol and should not be interpreted as an established dosage for use specifically together with a NAD+ precursor.
Resveratrol also has a relatively low bioavailability after oral administration.
A significant proportion of the orally administered dose is rapidly metabolised before reaching the systemic circulation, which presents a distinct pharmacokinetic limitation.
This issue is independent of problems concerning the absorption and metabolism of NAD+ precursors.
The optimal timing for taking this combination has also not been established.
There is no dedicated evidence to suggest that NAD+ precursors and resveratrol need to be taken simultaneously, at different times, in the morning, in the evening, or specifically with food to achieve the effect resulting from their combination.
In the case of NAD+ precursors, available pharmacokinetic data more strongly support regular, repeated intake rather than a specific optimal time of day.
Currently, there is no evidence that the addition of resveratrol changes this conclusion.
Combined NAD+/resveratrol products vs separate products
Commercial combination products often contain an NAD+ precursor, most commonly NR, along with resveratrol or a related polyphenol.
Such formulations are usually promoted on the basis of the previously described rationale related to sirtuins, but the presence of both ingredients in a commercial product does not mean that the exact formulation has been independently tested in a clinical trial.
No clinical trial evidence has been identified regarding specific commercial brands of products combining NAD+ and resveratrol discussed in this category.
Human studies relate to specific compounds and doses used in research conditions and cannot be automatically applied to every ratio of ingredients or formulation available on the market.
The separate products differ primarily in their greater flexibility.
Since an evidence-based optimal ratio of NAD+ precursor to resveratrol has not been established, separate formulations allow the amount of each compound to be considered independently based on the data available for the given ingredient.
Combination products are more convenient because both compounds are in a single formulation.
However, this convenience should not be equated with proof that the combination produces greater biological or clinical effects than the individual components used separately.
The cost also varies significantly between products.
A multi-ingredient supplement can be cheaper or more expensive than buying the ingredients separately, depending on the brand, dosage, serving size, form of the ingredients and manufacturing standards.
The most useful comparison should therefore be based on the quantity and form of each active ingredient, rather than merely on the label indicating a combination product.
Overall, current evidence does not confirm that the combined NAD+/resveratrol product is superior to separate formulations.
The most important differences concern composition, convenience, dosing flexibility, ingredient quality, and price, rather than a proven clinical advantage resulting from the combination itself.
Why does the combination of NAD+ and resveratrol remain popular?
The enduring popularity of the NAD+ and resveratrol combination is understandable, as both compounds have been linked to the same area of the biology of ageing.
NAD+ is essential for sirtuin activity, whereas resveratrol became widely known thanks to early studies suggesting direct activation of SIRT1 [1].
This created a biologically attractive concept that was easy to translate into supplement formulations.
However, the scientific picture became more complex when subsequent studies questioned the direct activation of SIRT1 by resveratrol under natural biochemical conditions [2].
At the same time, human research into NAD+ precursors has developed much faster than direct clinical trials regarding their combination with resveratrol.
As a result, the popularity of this combination is greater than the amount of direct human trial data confirming the synergy of both compounds.
The combination of NAD+ and resveratrol is therefore an example of a situation where a biologically interesting hypothesis, early experimental research and commercial popularity developed faster than confirmation in controlled clinical trials.
Limitations of current evidence
- No published, controlled human clinical trial specifically testing an NAD+ precursor in combination with resveratrol has been identified.
- The closest available human trial data concern NR combined with pterostilbene, which is a compound related to resveratrol, but chemically distinct [3].
- The frequently cited mechanism of direct activation of SIRT1 by resveratrol has been challenged by subsequent biochemical studies using natural, non-fluorescent substrates [1,2].
- The exact biological contribution of resveratrol to NAD+-related effects therefore remains uncertain.
- The NR study with pterostilbene showed an increase in NAD+ levels, but did not establish whether the stilbene compound provided any additional benefit over NR alone [3].
- A clinically optimal ratio of the NAD+ precursor to resveratrol has not been established.
- General dosage ranges for resveratrol come from studies evaluating other outcomes and should not be interpreted as an established dosage in combination with NAD+.
- Resveratrol has relatively low bioavailability following oral administration, which complicates the interpretation of studies on oral supplementation.
- There is no dedicated evidence determining the optimal time of day or the time dependence between taking NAD+ precursors and resveratrol.
- No clinical studies concerning specific commercial products combining NAD+ and resveratrol have been identified.
- Biological plausibility and pathway overlap do not in themselves prove clinical synergy or better outcomes resulting from the combination of both compounds.
Disclaimer
The article is strictly educational and summarises scientific research. It does not constitute medical advice or a recommendation for or against the use of NAD+, resveratrol, or their combined supplementation.
NAD+, its precursors and resveratrol should not be presented as FDA- or EMA-approved treatments for ageing, metabolic diseases, cardiovascular diseases, cognitive decline, or any other conditions, unless referring to a specific approved medicinal product and indication.
The scientific rationale for combining NAD+ precursors with resveratrol is based partly on mechanistic studies that are still the subject of debate, whereas direct, controlled human trial data regarding this specific combination are currently limited. Brand names have been included solely as examples of commercially available formulations and do not constitute a recommendation or evidence that a specific product has been clinically validated.
References
[1] Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., Scherer, B., & Sinclair, D. A. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425(6954), 191–196. https://doi.org/10.1038/nature01960
[2] Pacholec, M., Bleasdale, J. E., Chrunyk, B., Cunningham, D., Flynn, D., Garofalo, R. S., Griffith, D., Griffor, M., Loulakis, P., Pabst, B., Qiu, X., Stockman, B., Thanabal, V., Varghese, A., Ward, J., Withka, J., & Ahn, K. (2010). SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. Journal of Biological Chemistry, 285(11), 8340–8351. https://doi.org/10.1074/jbc.M109.088682
[3] Dellinger, R. W., Santos, S. R., Morris, M., Evans, M., Alminana, D., Guarente, L., & Marcotulli, E. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: A randomised, double-blind, placebo-controlled study. npj Aging and Mechanisms of Disease, 3, 17. https://doi.org/10.1038/s41514-017-0016-9